Andrew Emerson's most recent trade in Idexx Laboratories, Inc. was a trade of 4,270 Non-Qualified Stock Option (right-to-buy) done . Disclosure was reported to the exchange on Feb. 12, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Idexx Laboratories | Andrew Emerson J. | EVP, CFO and Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 4,270 | 4,270 | - | - | Non-Qualified Stock Option (right-to-buy) | |
| Idexx Laboratories | Andrew Emerson J. | EVP, CFO and Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 729 | 729 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Andrew Emerson J. | EVP, CFO and Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 284 | 284 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Andrew Emerson J. | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 194 | 581 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Andrew Emerson J. | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 194 | 4,280 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Andrew Emerson J. | EVP, CFO and Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 162 | 162 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories | Andrew Emerson J. | EVP, CFO and Treasurer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 629.35 per share. | 12 Feb 2026 | 123 | 4,222 (0%) | 0% | 629.3 | 77,410 | Common Stock |
| Idexx Laboratories | Andrew Emerson J. | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 94 | 93 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Andrew Emerson J. | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 94 | 4,044 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Andrew Emerson J. | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 65 | 193 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Andrew Emerson J. | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 65 | 4,345 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Andrew Emerson J. | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 61 | 3,950 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Andrew Emerson J. | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 61 | 0 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Andrew Emerson J. | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 42 | 83 | - | - | Restricted Stock Unit | |
| Idexx Laboratories | Andrew Emerson J. | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 42 | 4,086 (0%) | 0% | 0 | Common Stock | |
| Idexx Laboratories | Andrew Emerson | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 141.60 per share. | 07 Aug 2025 | 1,849 | 4,272 (0%) | 0% | 141.6 | 261,818 | Common Stock |
| Idexx Laboratories | Andrew Emerson | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2025 | 1,849 | 0 | - | - | Incentive Stock Option (right-to-buy) | |
| Idexx Laboratories | Andrew Emerson | EVP, CFO and Treasurer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 650.06 per share. | 07 Aug 2025 | 402 | 3,870 (0%) | 0% | 650.1 | 261,324 | Common Stock |